237 related articles for article (PubMed ID: 11159537)
1. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
Brender C; Nielsen M; Kaltoft K; Mikkelsen G; Zhang Q; Wasik M; Billestrup N; Odum N
Blood; 2001 Feb; 97(4):1056-62. PubMed ID: 11159537
[TBL] [Abstract][Full Text] [Related]
2. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
[TBL] [Abstract][Full Text] [Related]
3. Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses.
Ding Y; Chen D; Tarcsafalvi A; Su R; Qin L; Bromberg JS
J Immunol; 2003 Feb; 170(3):1383-91. PubMed ID: 12538698
[TBL] [Abstract][Full Text] [Related]
4. Thyrotropin-mediated repression of class II trans-activator expression in thyroid cells: involvement of STAT3 and suppressor of cytokine signaling.
Kim H; Suh JM; Hwang ES; Kim DW; Chung HK; Song JH; Hwang JH; Park KC; Ro HK; Jo EK; Chang JS; Lee TH; Lee MS; Kohn LD; Shong M
J Immunol; 2003 Jul; 171(2):616-27. PubMed ID: 12847226
[TBL] [Abstract][Full Text] [Related]
5. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines.
Nielsen M; Kaltoft K; Nordahl M; Röpke C; Geisler C; Mustelin T; Dobson P; Svejgaard A; Odum N
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6764-9. PubMed ID: 9192639
[TBL] [Abstract][Full Text] [Related]
6. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C.
Radaeva S; Jaruga B; Kim WH; Heller T; Liang TJ; Gao B
Biochem J; 2004 Apr; 379(Pt 1):199-208. PubMed ID: 14690454
[TBL] [Abstract][Full Text] [Related]
8. Various cytokines modulate ICAM-1 shedding on melanoma- and CTCL-derived cell lines: inverse regulation of ICAM-1 shedding in a Sézary cell line by interferon-gamma.
Dummer R; Sigg-Zemann S; Kalthof K; Muletta S; Meyer JC; Burg G
Dermatology; 1994; 189(2):120-4. PubMed ID: 7915555
[TBL] [Abstract][Full Text] [Related]
9. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha.
Brender C; Lovato P; Sommer VH; Woetmann A; Mathiesen AM; Geisler C; Wasik M; Ødum N
Leukemia; 2005 Feb; 19(2):209-13. PubMed ID: 15618960
[TBL] [Abstract][Full Text] [Related]
10. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3.
Sommer VH; Clemmensen OJ; Nielsen O; Wasik M; Lovato P; Brender C; Eriksen KW; Woetmann A; Kaestel CG; Nissen MH; Ropke C; Skov S; Ødum N
Leukemia; 2004 Jul; 18(7):1288-95. PubMed ID: 15141228
[TBL] [Abstract][Full Text] [Related]
11. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation.
Berlato C; Cassatella MA; Kinjyo I; Gatto L; Yoshimura A; Bazzoni F
J Immunol; 2002 Jun; 168(12):6404-11. PubMed ID: 12055259
[TBL] [Abstract][Full Text] [Related]
12. SHP2 regulates IL-2 induced MAPK activation, but not Stat3 or Stat5 tyrosine phosphorylation, in cutaneous T cell lymphoma cells.
Lundin Brockdorff J; Woetmann A; Mustelin T; Kaltoft K; Zhang Q; Wasik MA; Röpke C; Ødum N
Cytokine; 2002 Nov; 20(4):141-7. PubMed ID: 12543077
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin induces SOCS-1 (suppressor of cytokine signaling-1) and SOCS-3 in FRTL-5 thyroid cells.
Park ES; Kim H; Suh JM; Park SJ; Kwon OY; Kim YK; Ro HK; Cho BY; Chung J; Shong M
Mol Endocrinol; 2000 Mar; 14(3):440-8. PubMed ID: 10707961
[TBL] [Abstract][Full Text] [Related]
14. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3.
Nielsen M; Nissen MH; Gerwien J; Zocca MB; Rasmussen HM; Nakajima K; Röpke C; Geisler C; Kaltoft K; Ødum N
Blood; 2002 Feb; 99(3):973-7. PubMed ID: 11807001
[TBL] [Abstract][Full Text] [Related]
16. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL).
Bunn PA; Foss FM
J Cell Biochem Suppl; 1996; 24():12-23. PubMed ID: 8806090
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone down-regulation of Interleukin-1beta and Interleukin-6 induced acute phase protein gene expression is associated with increased gene expression of suppressor of cytokine signal-3.
Wu X; Herndon DN; Wolf SE
Shock; 2003 Apr; 19(4):314-20. PubMed ID: 12688541
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling.
Lejeune D; Demoulin JB; Renauld JC
Biochem J; 2001 Jan; 353(Pt 1):109-116. PubMed ID: 11115404
[TBL] [Abstract][Full Text] [Related]
19. Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1.
Federici M; Giustizieri ML; Scarponi C; Girolomoni G; Albanesi C
J Immunol; 2002 Jul; 169(1):434-42. PubMed ID: 12077274
[TBL] [Abstract][Full Text] [Related]
20. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells.
Sakai I; Takeuchi K; Yamauchi H; Narumi H; Fujita S
Blood; 2002 Oct; 100(8):2926-31. PubMed ID: 12351404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
